P3 Health Partners (PIII) EBITDA (2021 - 2025)

P3 Health Partners (PIII) has reported EBITDA for 5 consecutive years, with -$153.4 million the latest figure, recorded in Q4 2025.

• EBITDA for Q4 2025 came in at -$153.4 million, down 11.29% year-over-year; the trailing twelve-month figure through Dec 2025 was -$268.1 million (up 15.76% YoY), and the FY2025 annual result was -$268.1 million, up 15.76% from the prior year.
• EBITDA was -$153.4 million for Q4 2025 at P3 Health Partners, down from -$43.7 million in the prior quarter.
• Over five years, EBITDA peaked at $564.4 million in Q4 2021 and troughed at -$911.6 million in Q2 2022.
• Average EBITDA over 5 years is -$90.6 million, with a median of -$43.5 million recorded in 2024.
• Year-over-year, EBITDA tumbled 3410.01% in 2022 and jumped 97.76% in 2023.
• Over 5 years, EBITDA stood at $564.4 million in 2021, then sank by 194.96% to -$535.9 million in 2022, then surged by 88.1% to -$63.8 million in 2023, then tumbled by 116.13% to -$137.8 million in 2024, then decreased by 11.29% to -$153.4 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$153.4 million in Q4 2025, -$43.7 million in Q3 2025, and -$33.5 million in Q2 2025.